share_log

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

Monopar Therapeutics和其他2只股票以低于2美元的价格被内部人士购买
Benzinga ·  06/03 07:41

The Dow Jones index closed higher by around 575 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道琼斯指数周五收涨约575点。当内部人士购买或出售股票时,表明他们对公司前景的信心或担忧。对于有兴趣购买低价股的投资者和交易者来说,可以将此视为其整体投资或交易决策的因素之一。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是几个近期关于低价股的值得关注的内部交易。了解更多,请查看Benzinga内幕交易平台。

Grove Collaborative Holdings

Grove Collaborative Holdings

  • The Trade: Grove Collaborative Holdings, Inc. (NYSE:GROV) President and CEO Jeffrey Michael Yurcisin bought a total of 17,100 shares at an average price of $1.63. To acquire these shares, it cost around $27,951.
  • What's Happening: On May 14, Grove Collaborative posted a narrower-than-expected quarterly loss.
  • What Grove Collaborative Holdings Does: Grove Collaborative Holdings Inc is engaged in providing consumer products.
  • 交易:Grove Collaborative Holdings,Inc.(纽交所:GROV)总裁兼首席执行官Jeffrey Michael Yurcisin以平均价格1.63美元买入了共计17100股。要获得这些股票,这需要花费约27951美元。
  • 近期动态:5月14日,Grove Collaborative发布了比预期亏损更小的季度财报。
  • Grove Collaborative Holdings的业务是提供消费品。

Fresh Tracks Therapeutics

Fresh Tracks Therapeutics

  • The Trade: Fresh Tracks Therapeutics, Inc. (OTC:FRTX) 10% owner Exploration Capital, LLC acquired a total of 10,434 shares at an average price of $0.92. To acquire these shares, it cost around $9,580.
  • What's Happening: The company's stock fell around 3% over the past month.
  • 交易:Fresh Tracks Therapeutics,Inc.(场外交易:FRTX)10%股东Exploration Capital,LLC以平均价格0.92美元收购了10434股。获得这些股票需要花费约9580美元。
  • 近期动态:该公司股票在过去一个月中下跌了约3%。

Monopar Therapeutics

Monopar Therapeutics

  • The Trade: Monopar Therapeutics Inc. (NASDAQ:MNPR) Chief Operating Officer Andrew Cittadine acquired a total of 36,000 shares at an average price of $0.64. The insider spent around $23,051 to buy those shares.
  • What's Happening: On May 24, Monopar said its CFO Kim R. Tsuchimoto will be retiring.
  • What Monopar Therapeutics Does: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.
  • 交易:Monopar Therapeutics Inc.(纳斯达克代码:MNPR)首席运营官Andrew Cittadine以平均价格0.64美元买入了共计36000股。这位内部人士花费约23051美元购买这些股票。
  • 近期动态:5月24日,Monopar表示其首席财务官Kim R. Tsuchimoto将退休。
  • Monopar Therapeutics Inc是一家临床阶段的生物制药公司,致力于开发用于延长癌症患者寿命或提高生活质量的专有治疗方法。

Now Read This: Science Applications International, Autodesk And 3 Stocks To Watch Heading Into Monday

现在读此:科学应用国际、欧特克和3支周一值得关注的股票

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发